https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia

FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia

The U.S. Food and Drug Administration (FDA) approved Wayrilz (rilzabrutinib) tablets to treat adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to immunoglobulins, anti-D therapy, or corticosteroids.

administrator

Related Articles